

Kluwer Patent Blog

Esomeprazole - process patent, Bailiff's Court Frederiksberg (Højesteret), 28 February 2011

Anders Valentin (Bugge Valentin) · Thursday, July 7th, 2011

AstraZeneca enforced its patent for an asymmetrical synthetic route to obtain esomeprazole in Denmark. The API manufacturer of the allegedly infringing pharmaceutical had developed its own- independent synthetic route with a significantly lower yield and had applied for a European patent for that process. AstraZeneca alleged that the detection of trace amounts (ppb) of certain compounds in the allegedly infringing product indicated that the patented process had been employed for the manufacture of the pharmaceutical. The Court upheld the injunction which was granted in summary proceedings.

A **full summary** of this case has been published on **Kluwer IP Law**.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).



Want to improve your IP strategy?

- Manual of Industrial Property
- IP Analytics
- Visser – Annotated European Patent Convention

230+ jurisdictions
36,000+ cases
100+ books
600+ IP law professionals as authors

Request a free demo now
KluwerIPLaw.com

Wolters Kluwer

This entry was posted on Thursday, July 7th, 2011 at 11:34 am and is filed under (Indirect) infringement, Case Law, Denmark, Enforcement, Injunction

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.